Mortgage Rates Decrease

MCLEAN, Va., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing the 30-year fixed-rate mortgage (FRM) averaged 6.89%.

“The 30-year fixed-rate mortgage decreased this week, now averaging 6.89%,” said Sam Khater, Freddie Mac’s Chief Economist. “Mortgage rates have been stable over the last month and incoming data suggest the economy remains on firm footing. Even though rates are higher compared to last year, the last two weeks of purchase applications are modestly above what we saw a year ago, indicating some latent demand in the market.”

News Facts

• The 30-year FRM averaged 6.89% as of February 6, 2025, down from last week when it averaged 6.95%. A year ago at this time, the 30-year FRM averaged 6.64%.
• The 15-year FRM averaged 6.05%, down from last week when it averaged 6.12%. A year ago at this time, the 15-year FRM averaged 5.90%.

The PMMS® is focused on conventional, conforming, fully amortizing home purchase loans for borrowers who put 20% down and have excellent credit. For more information, view our Frequently Asked Questions.

Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability, affordability and equity in the housing market throughout all economic cycles. Since 1970, we have helped tens of millions of families buy, rent or keep their home. Learn More: Website | Consumers | X | LinkedIn | Facebook | Instagram | YouTube

MEDIA CONTACT:
Angela Waugaman
(703)714-0644
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c4d6e508-93b2-4fc3-8373-6fa4cc8dfdd8

Primary Mortgage Market Survey®

U.S. weekly average mortgage rates as of 02/06/2025

You May Also Be Interested In

• Defiance ETFs Announces Temporary Trading Halt of the Defiance Daily 2X Space ETF (SPCL) on Cboe BZX Exchange, Inc.
• Dr. Jose Jacob Scholarship for Future Doctors Opens 2027 Applications to Support the Next Generation of Physicians Across the United States
• Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1